IX.q

Obstructive sleep apneas

Or worsening of preexisting SAS

Last update : 31/08/2015
 

Causative drugs

5

Etanercept

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ar X - Systemic conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease
XI.ad XI - Miscellaneous
XI.ad - Granulomas on tattoo edges
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
1

TNF-alpha antagonists/inhibitors

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.d III - Pulmonary hemorrhage
III.d - Alveolar hemorrhage, diffuse, ANCA-positive or related
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.p X - Systemic conditions, syndromes and reactions
X.p - Serum sickness-like reaction
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.x X - Systemic conditions, syndromes and reactions
X.x - Subclinical ANCA positivity
X.ae X - Systemic conditions, syndromes and reactions
X.ae - Antisynthetase antibodies (ASA)-ASA syndrome
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus neoformans pulmonary infection
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
1

Tobacco smoke - Cigarette smoking

I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.ai I - Interstitial/parenchymal lung disease
I.ai - Pulmonary fibrosis and emphysema syndrome
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.g IV - Airway involvement
IV.g - Syncope - Cough syncope
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
X.ah X - Systemic conditions, syndromes and reactions
X.ah - Granulomatosis with polyangiitis (w/wo ANCA) or flare of
XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XI.ah XI - Miscellaneous
XI.ah - Fainting - Syncope
XI.an XI - Miscellaneous
XI.an - Disrupted lung surfactant function
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIV.c XIV - Hemoglobinopathies-Abnormal hemoglobins states (acquired)
XIV.c - Carboxyhemoglobinemia
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.y XV - Pulmonary pathology
XV.y - Path: Respiratory bronchiolitis (RB-ILD-pattern)
XV.z XV - Pulmonary pathology
XV.z - Path: Chronic obliterative broncholitis (see also IVc, IVn)
XV.ay XV - Pulmonary pathology
XV.ay - Path: Smoking-related interstitial fibrosis (SRIF). Respiratory bronchiolitis with fibrosis
XV.bw XV - Pulmonary pathology
XV.bw - Path: Airspace enlargement with fibrosis
XVI.p XVI - Imaging
XVI.p - Imaging: Small irregular opacities - ILA - Diffuse reticulation
XVI.ac XVI - Imaging
XVI.ac - Imaging: A generalized increase in lung density
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
1